MPAM
CRNX icon

Monarch Partners Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Monarch Partners Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$2.36M Sell
128,974
-1,886
-1% -$33.2K 0.7% 65
2022
Q3 		$2.57M Buy
+130,860
New +$2.67M 0.77% 58

Other funds holding CRNX

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Monarch Partners Asset Management's CRNX Position: Q4 2022 in Review

Monarch Partners Asset Management reduced its Crinetics Pharmaceuticals (CRNX) stake by 1.4% in Q4 2022, selling an estimated $33.2K and leaving 128,974 shares worth $2.36M. The position accounts for 0.7% of the portfolio, ranked #65.

Monarch Partners Asset Management first reported a position in CRNX in Q3 2022 and has held it in 2 quarters since. The position peaked at $2.57M in Q3 2022. 122 funds tracked by Wall St. Rank hold CRNX as of Q4 2022.

  • Monarch Partners Asset Management held 128,974 shares of Crinetics Pharmaceuticals worth $2.36M as of Q4 2022.
  • Monarch Partners Asset Management sold 1,886 Crinetics Pharmaceuticals shares in Q4 2022, an estimated $33.2K.
  • Crinetics Pharmaceuticals made up 0.7% of Monarch Partners Asset Management's portfolio in Q4 2022, its #65 holding.
  • Monarch Partners Asset Management first reported a position in Crinetics Pharmaceuticals in Q3 2022 and has held it in 2 quarters since.
  • Monarch Partners Asset Management's Crinetics Pharmaceuticals position peaked at $2.57M in Q3 2022.
  • 122 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2022.

Based on Monarch Partners Asset Management's 13F filing for Q4 2022, filed 2 Feb 2023.